Table 2.
Crossed metabolic pathways of rifapentine/rifampicin and oral antidiabetics
| Oral hypoglycemic agent | Antituberculosis drug
|
|
|---|---|---|
| Rifapentine | Rifampicin | |
| Meglitinides | ||
| Nateglinide (Starlix®) | 3A4/2C9 | 3A4/2C9 |
| Repaglinide (Prandin®) | 3A4/2C8 | 3A4/2C8 |
| Thiazolidinediones | ||
| Pioglitazone (Actos®) | 3A4/2C8 | 3A4/2C8 |
| Rosiglitazone (Avandia®) | 2C8/9 | 2C8/9 |
| Sulfonylureas | ||
| Glibenclamide (Glyburide®) | 3A4 | 3A4 |
| Gliclazide (Diamicron®) | 2C8/9 | 2C8/9/19 |
| Gliquidone (Glurenorm®) | 3A4/2C9 | 3A4/2C9/19/1A2 |
| DPP-IV inhibitors | ||
| Sitagliptin (Januvia®) | 3A4/2C8 | 3A4/2C8 |
| Saxagliptin (Onglyza®) | 3A4 | 3A4 |
| Other | ||
| Bromocriptine mesylate (Cycloset®) | 3A4 | 3A4 |
Abbreviation: DPP-IV, dipeptidyl peptidase IV.